Ligand Pharmaceuticals Incorporated
LGND · NASDAQ Global Market · USD
314,15USD
+7,95 (+2,60 %)Stand 9. Nov., 21:00
Nachbörslich313,81−0,34 (−0,11 %)19:46 ET
Kennzahlen
- Eröffnung
- 310,34
- Vortag
- 306,20
- Tagesspanne
- 307,17 – 315,81
- 52 Wochen
- 175,89 – 326,63
- Volumen
- 138.279
- Ø Volumen
- 259.298
- Börsenwert
- 6,28 Mrd. $
- KGV
- 121,3
- Gewinn je Aktie (TTM)
- 2,24
- Dividendenrendite
- 0,0 %
- Beta
- 1,0
- Nächste Zahlen
- 25. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 268,09 Mio. | 167,13 Mio. | 131,31 Mio. | 196,25 Mio. | 241,54 Mio. |
| Herstellungskosten | 6,59 Mio. | 11,07 Mio. | 35,05 Mio. | 52,83 Mio. | 62,18 Mio. |
| Bruttogewinn | 261,5 Mio. | 156,06 Mio. | 96,27 Mio. | 143,42 Mio. | 179,37 Mio. |
| Forschung und Entwicklung | 81,18 Mio. | 21,43 Mio. | 24,54 Mio. | 36,08 Mio. | 32,11 Mio. |
| Vertrieb und Verwaltung | 92,45 Mio. | 78,65 Mio. | 52,79 Mio. | 70,06 Mio. | 46,79 Mio. |
| Operatives Ergebnis | 47,2 Mio. | −22,61 Mio. | 11,94 Mio. | 3,04 Mio. | 103,85 Mio. |
| EBITDA | 192,74 Mio. | 40,79 Mio. | 100,84 Mio. | 81,2 Mio. | 142,77 Mio. |
| Nettogewinn | 124,45 Mio. | −4,03 Mio. | 52,15 Mio. | −33,36 Mio. | 57,14 Mio. |
| Gewinn je Aktie (verwässert) | 6,13 | -0,22 | 2,94 | -1,98 | 3,34 |
Umsatz nach Segment
Produkte · FY 2025
- Royalty161 Mio. $32,54 %+48,02 %
- Intangible Royalty Assets132,53 Mio. $26,79 %+39,03 %
- Contract Revenue66,87 Mio. $13,52 %+143,38 %
- Material Sales, Captisol, Core40,21 Mio. $8,13 %+30,21 %
- Royalty, Kyprolis35,53 Mio. $7,18 %−7,41 %
- Financial Royalty Assets28,47 Mio. $5,75 %+111,75 %
- Royalty, Other10,37 Mio. $2,10 %+15,89 %
- License Fees6,99 Mio. $1,41 %+259,47 %
- Service6,81 Mio. $1,38 %−73,32 %
- Royalty, Evomela5,94 Mio. $1,20 %−31,53 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 121,3
- Kurs-Umsatz-Verhältnis
- 24,8
- Kurs-Buchwert-Verhältnis
- 6,5
- PEG
- 14,5
- Bruttomarge
- 107,1 %
- Operative Marge
- 11,9 %
- Nettomarge
- 20,3 %
- Verschuldungsgrad
- 1,2
- EV/EBITDA
- 91,7
- Eigenkapitalrendite
- 5,2 %
- Kapitalrendite (ROIC)
- 1,3 %
- Free-Cashflow-Rendite
- 1,4 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 97,5 % | 93,4 % | 73,3 % | 73,1 % | 74,3 % |
| Operative Marge | 17,6 % | −13,5 % | 9,1 % | 1,5 % | 43,0 % |
| Nettomarge | 46,4 % | −2,4 % | 39,7 % | −17,0 % | 23,7 % |
| KGV | 29,4 | -487,0 | 23,6 | -33,7 | 27,8 |
| Kurs-Umsatz-Verhältnis | 13,6 | 11,7 | 9,4 | 5,7 | 6,6 |
| Kurs-Buchwert-Verhältnis | 3,6 | 2,4 | 1,8 | 1,9 | 2,0 |
| Verschuldungsgrad | 0,4 | 0,0 | 0,0 | 0,1 | 0,4 |
| Liquidität 3. Grades | 22,2 | 8,9 | 14,1 | 2,7 | 11,2 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 3,93 Mrd. | 1,89 Mrd. | 1,22 Mrd. | 1,17 Mrd. | 1,91 Mrd. |
| EV/EBITDA | 20,4 | 46,4 | 12,1 | 14,4 | 13,4 |
| Eigenkapitalrendite | 12,2 % | −0,5 % | 7,4 % | −5,6 % | 7,0 % |
| Kapitalrendite (ROIC) | 2,4 % | 4,0 % | 1,3 % | −0,1 % | 8,3 % |
| Free-Cashflow-Rendite | 1,3 % | 3,9 % | −0,3 % | 10,6 % | 4,4 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +60,4 % | +27,3 % | −33,1 % | −18,8 % | +47,7 % |
| Bruttogewinn | +67,6 % | +62,1 % | −32,9 % | −20,0 % | +34,7 % |
| Operatives Ergebnis | +308,8 % | −289,3 % | +293,2 % | −97,1 % | +176,9 % |
| Nettogewinn | +3.186,6 % | −107,7 % | +256,3 % | −158,4 % | +2.014,2 % |
| Gewinn je Aktie | +2.886,4 % | −107,5 % | +248,5 % | −159,3 % | +1.955,6 % |
| Freier Cashflow | −36,8 % | +1.912,0 % | −103,6 % | +71,2 % | +39,7 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 13Kaufen
- 4Halten
- 1Verkaufen
- 0Stark verkaufen
Kursziel
342,00
Durchschnitt · +8,87 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 291,96 Mio. | 384,46 Mio. | 456,81 Mio. |
| Umsatz (Tief – Hoch) | 286,39 Mio. – 297,37 Mio. | 354,12 Mio. – 406,28 Mio. | 411,6 Mio. – 494,97 Mio. |
| Gewinn je Aktie (Ø) | 9,55 | 12,01 | 14,08 |
| Gewinn je Aktie (Tief – Hoch) | 9,34 – 9,69 | 11,25 – 12,56 | 13,50 – 14,80 |
| Analysten | 7 | 7 | 4 |
Letzte Änderungen
- Citigroup5. Nov. 2026Buy
- RBC Capital30. Okt. 2026Outperform
- HC Wainwright & Co.24. Sept. 2026Buy
- Citigroup23. Sept. 2026Buy
- RBC Capital7. Aug. 2026Outperform
- HC Wainwright & Co.6. Aug. 2026Buy
- Oppenheimer3. Aug. 2026Outperform
- RBC Capital15. Juli 2026Outperform
Quartalszahlen
Nächste Zahlen: 25. Feb. 2027| Okt. 2026 | Aug. 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 2,33 | 2,01 | 1,84 | 1,46 | 1,97 | 1,42 | 1,21 | 1,37 |
| Gewinn je Aktie · Tatsächlich | 2,67 | 2,37 | 1,63 | 2,02 | 3,09 | 1,60 | 1,33 | -1,64 |
| Abweichung | +14,59 % | +17,91 % | −11,41 % | +38,36 % | +56,85 % | +12,68 % | +9,92 % | −219,71 % |
| Umsatz · Tatsächlich | 78,75 Mio. | 63,69 Mio. | 51,72 Mio. | 59,67 Mio. | 115,46 Mio. | 47,63 Mio. | 45,33 Mio. | 42,81 Mio. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 2. Juli 2010 | – | 0,12 |
| 3. Apr. 2007 | 19. Apr. 2007 | 2,50 |
Aktiensplits
- 2. Nov. 20221603:1000
- 19. Nov. 20101:6
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 113,77 %
- Investoren mit 13F-Meldung
- 432
Größte Investoren
- BLACKROCK, INC.15,46 %3,1 Mio.
- INVESCO LTD.5,99 %1,2 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC5,67 %1,14 Mio.
- JUPITER TOPCO LLC5,19 %1,04 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC4,34 %870.950
- STATE STREET CORP4,16 %826.539
- FMR LLC3,80 %762.827
- FRANKLIN TEMPLETON INC3,75 %752.044
Insider-Geschäfte
- Aryeh Jason4. Nov. 2026 · directorVerkauf282 Aktien · 319,99
- Reardon Andrew2. Nov. 2026 · officer: CLO & SecretaryKauf5000 Aktien · 52,27
- Reardon Andrew2. Nov. 2026 · officer: CLO & SecretaryVerkauf283 Aktien · 307,39
- Reardon Andrew2. Nov. 2026 · officer: CLO & SecretaryVerkauf708 Aktien · 308,43
- Reardon Andrew2. Nov. 2026 · officer: CLO & SecretaryVerkauf522 Aktien · 309,91
- Reardon Andrew2. Nov. 2026 · officer: CLO & SecretaryVerkauf490 Aktien · 310,61
- Reardon Andrew2. Nov. 2026 · officer: CLO & SecretaryVerkauf520 Aktien · 311,72
- Reardon Andrew2. Nov. 2026 · officer: CLO & SecretaryVerkauf634 Aktien · 312,85
Vergleichbare Unternehmen
Über das Unternehmen
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Führung
- Todd C. DavisChief Executive Officer & Director
- Octavio EspinozaChief Financial Officer
- Andrew T. ReardonChief Legal Officer & Secretary
- Melanie J. HermanExecutive Director of Investor Relations and Financial Planning & Analysis
- Richard BaxterSenior VP of Investment Operations
- Marjorie FackovecHead of People Operations
- CEO
- Todd C. Davis
- Mitarbeitende
- 47
- Hauptsitz
- Jupiter, FL, US
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 18. Nov. 1992
- Website
- ligand.com
Nachrichten
- Defense World · 7. Nov., 5:35Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells $1,566,100.00 in Stock
- Defense World · 7. Nov., 5:05Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells $1,566,100.00 in Stock
- Seeking Alpha · 4. Nov., 16:21Ligand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A Buy
- Seeking Alpha · 30. Okt., 0:58Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call Transcript
- MarketBeat · 29. Okt., 15:15What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call
- GlobeNewsWire · 29. Okt., 7:00Ligand Reports Third Quarter 2026 Financial Results
- GlobeNewsWire · 27. Okt., 16:01Ligand to Participate in November Investor Conferences
- GlobeNewsWire · 22. Okt., 16:01Ligand to Host Investor Day on December 8, 2026
- GlobeNewsWire · 15. Okt., 7:00Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
- GlobeNewsWire · 24. Sept., 7:00Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.